GenEditBio is a clinical-stage biotechnology company focused on CRISPR-based precision genome editing therapies. The company aims to deliver affordable, in-body “DNA surgery” to treat genetic diseases with unmet medical needs, using novel Cas nucleases and safe cargo delivery via lipid nanoparticles (LNPs) and engineered protein delivery vehicles (PDVs). Its pipeline targets in vivo genome-editing applications across ocular, metabolic, and rare diseases, with the goal of curing genetic conditions at their roots. Headquarters and research activities are based in Hong Kong and Beijing, reflecting its global development footprint.
No recent deals for this company.